Among patients with DLBCL, most exhibited high‐risk clinical features such as an age‐adjusted International Prognostic Index (aaIPI) of 2–3 and positive interim PET scan results after induction treatment, or biological high‐risk features including double expression, double‐/triple‐hit, and TP53 alterations (Table S2). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.